Cytokinetics Halts Development of ALS Candidate Tirasemtiv after Phase III Failure

Cytokinetics said today it has halted development of its lead drug tirasemtiv after it failed a Phase III trial in patients with amyotrophic lateral sclerosis (ALS).Without offering details, Cytokinetics said tirasemtiv missed its primary endpoint in the Phase III VITALITY-ALS (Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year in ALS) by failing to show change from baseline in slow vital capacity (SVC) following 24 weeks of double-blind, pl